Christina Funk, Nadja Uhlig, Zsolt Ruzsics, Florentin Baur, Matthias Peindl, Sarah Nietzer, Karina Epting, Gabriele Vacun, Gudrun Dandekar, Catherine Botteron, Christian Werno, Thomas Grunwald, Susanne M Bailer
Viruses are able to efficiently penetrate cells, multiply, and eventually kill infected cells, release tumor antigens, and activate the immune system. Therefore, viruses are highly attractive novel agents for cancer therapy. Clinical trials with first generations of oncolytic viruses (OVs) are very promising but show significant need for optimization. The aim of TheraVision was to establish a broadly applicable engineering platform technology for combinatorial oncolytic virus and immunotherapy. Through genetic engineering, an attenuated herpes simplex virus type 1 (HSV1) was generated that showed increased safety compared to the wild-type strain...
March 21, 2024: Mol Ther Oncol